To understand the efficacy of EZH2 catalytic inhibition across lineage subtypes of prostate cancer, we performed cell viability and tumor growth experiments upon treatment with tazemetostat in a diverse panel of advanced prostate cancer models. This evidence concerns the gene EZH2 and neoplasm.